The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Real‑world experience with marstacimab in severe and non‑severe hemophilia
Akshat Jain, MD, MPH, FRCP, Loma Linda University, San Bernardino, CA, discusses real-world experience with the anti-tissue factor pathway inhibitor (TFPI) agent marstacimab in severe and non-severe hemophilia. He highlights the potential of marstacimab to revolutionize treatment for patients with hemophilia A and B, including marginalized groups such as women with hemophilia and those with moderate hemophilia. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
